Atara Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	151.93	128.94	8.57	63.57	20.34	-	Upgrade
Revenue Growth (YoY)	51.27%	1404.02%	-86.52%	212.55%	-	-	Upgrade
Cost of Revenue	80.88	168.74	228.05	269.99	282	244.65	Upgrade
Gross Profit	71.05	-39.8	-219.48	-206.42	-261.66	-244.65	Upgrade
Selling, General & Admin	28.36	38.53	49.8	68.13	78.8	64.4	Upgrade
Operating Expenses	28.36	38.53	49.8	68.13	78.8	64.4	Upgrade
Operating Income	42.69	-78.33	-269.28	-274.55	-340.46	-309.05	Upgrade
Interest Expense	-3.92	-4.62	-5.29	-0.37	-	-	Upgrade
Interest & Investment Income	1.18	2.11	5.43	3.06	2.14	3.28	Upgrade
Other Non Operating Income (Expenses)	-0.07	0.53	-0.25	-0.7	-	-	Upgrade
EBT Excluding Unusual Items	39.88	-80.31	-269.38	-272.56	-338.33	-305.78	Upgrade
Merger & Restructuring Charges	-16.46	-5.11	-6.73	-5.96	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	-1.77	-0.83	Upgrade
Gain (Loss) on Sale of Assets	-0	-	-	50.24	-	-	Upgrade
Pretax Income	23.41	-85.42	-276.11	-228.29	-340.1	-306.61	Upgrade
Income Tax Expense	0.01	-0.01	0.02	0.01	0.05	0.02	Upgrade
Net Income	23.4	-85.4	-276.13	-228.3	-340.14	-306.62	Upgrade
Net Income to Common	23.4	-85.4	-276.13	-228.3	-340.14	-306.62	Upgrade
Shares Outstanding (Basic)	12	7	4	4	4	3	Upgrade
Shares Outstanding (Diluted)	12	7	4	4	4	3	Upgrade
Shares Change (YoY)	102.28%	76.77%	3.83%	8.88%	26.63%	44.17%	Upgrade
EPS (Basic)	1.98	-11.41	-65.19	-55.96	-90.78	-103.63	Upgrade
EPS (Diluted)	1.97	-11.41	-65.19	-55.96	-90.78	-103.63	Upgrade
Free Cash Flow	-69.8	-68.96	-194.2	-274.62	-231.1	-185.27	Upgrade
Free Cash Flow Per Share	-5.86	-9.21	-45.84	-67.32	-61.68	-62.62	Upgrade
Gross Margin	46.76%	-30.87%	-	-	-	-	Upgrade
Operating Margin	28.09%	-60.75%	-3140.98%	-431.86%	-1673.85%	-	Upgrade
Profit Margin	15.40%	-66.23%	-3220.88%	-359.12%	-1672.28%	-	Upgrade
Free Cash Flow Margin	-45.95%	-53.49%	-2265.25%	-431.98%	-1136.19%	-	Upgrade
EBITDA	44.85	-73.28	-264.45	-268.9	-331.12	-300.72	Upgrade
EBITDA Margin	29.52%	-56.83%	-	-	-	-	Upgrade
D&A For EBITDA	2.17	5.05	4.83	5.65	9.35	8.33	Upgrade
EBIT	42.69	-78.33	-269.28	-274.55	-340.46	-309.05	Upgrade
EBIT Margin	28.09%	-60.75%	-	-	-	-	Upgrade
Revenue as Reported	128.94	128.94	8.57	63.57	-	-	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q